Double-Barreled CAR-T cells take aim at tough leukemia

NCT ID NCT03330691

Ongoing Disease control Sponsor: Seattle Children's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new type of immunotherapy for children and young adults with leukemia that has come back or not responded to treatment. The therapy uses the patient's own immune cells, modified to recognize two different targets (CD19 and CD22) on leukemia cells, to try to kill them more effectively. The main goals are to see if the treatment is safe and if enough of these special cells can be made for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

leukemia lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA LYMPHOMA

Contacts and locations

Locations

Children's Hospital Los Angeles

Los Angeles, California, 90027, United States
Children's National Medical Center

Washington D.C., District of Columbia, 20010, United States
Children's and Women's Health Centre of British Columbia

Vancouver, British Columbia, V6H 3V4, Canada
Riley Hospital for Children

Indianapolis, Indiana, 46202, United States
Seattle Children's Hospital

Seattle, Washington, 98105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.